CLINICAL TRIAL
Published on 19 May 2025
A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibitor, in patients with mild to moderate atopic dermatitis: a proof-of-concept study with Post-hoc biomarker analysis
doi 10.3389/fimmu.2025.1560447
- 799 views